Clinical-stage biotechnology company Lipella Pharmaceuticals Inc (NASDAQ:LIPO) announced on Thursday the launch of an Oral Lichen Planus (OLP) Patient Registry.

This online platform aims to facilitate research and development of new treatments for OLP, a chronic inflammatory disease affecting the mouth. Symptoms include burning pain, white patches, swollen tissue and open sores.

Currently, there are no FDA-approved therapies for OLP.

The registry provides information about the investigational study of LP-310, an oral rinse derived from Lipella's lead candidate, LP-10. LP-310 has received FDA approval for clinical evaluation in treating OLP.